Patent US2324193A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4352791A Expired / Lapsed US ⏱️ 0.0 years remaining

Potassium replacement therapy

Assignee: Alza Corp
•
Filing: 1981-04-27
•
Granted: 1982-10-05
•
Expires: 2001-04-27
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A composition is disclosed comprising potassium chloride and a therapeutically acceptable salicylate salt or salicylic acid. The composition is useful for potassium therapy.

Inventors

  • 👤 Alejandro Zaffaroni
  • 👤 John Fara

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 14:41
CPC Classifications
A; A61; A61K; A61K33/00; A61K33/14

Claims Analysis

Total Claims: 25
Claim 1
Independent Claim 69 words
A method for treating potassium depletion in an animal in need of potassium replacement, which method comprises administering orally to the animal from 15 milligrams to 1200 milligrams of potassium chloride and an effective amount of a member selected from the group consisting essentially of salicyclic acid and its pharmaceutically acceptable salicylate salts for lessening the incidence of unwanted side effects associated with the therapeutic use of potassium chloride.
Claim 2
Independent Claim 69 words
A method for treating potassium depletion in an animal in need of potassium replacement, which method comprises administering orally to the animal from 15 milligrams to 1200 milligrams of potassium chloride and an effective amount of a member selected from the group consisting essentially of salicyclic acid and its pharmaceutically acceptable salicylate salts for lessening the incidence of unwanted side effects associated with the therapeutic use of potassium chloride.
Claim 3
Dependent Claim 42 words
The method for treating potassium depletion according to claim 1 wherein the animal is a human, the potassium chloride is administered as potassium replacement therapy for reversing the potassium depletion in the human, and the salicylate salt administered therewith is sodium salicylate.
Claim 4
Dependent Claim 40 words
The method for treating potassium depletion according to claim 1 wherein the animal is a human, the potassium chloride is administered as potassium replacement therapy for reversing potassium depletion in the human, and the salicylate salt administered is potassium salicylate.
Claim 5
Dependent Claim 55 words
The method for treating potassium depletion according to claim 1 wherein the animal is a human, the potassium chloride is administered as potassium replacement therapy for reversing potassium depletion in the human, and the member selected from the group consisting of salicylic acid and its pharmaceutically acceptable salts is administered simultaneously with the potassium chloride.
Claim 6
Dependent Claim 25 words
The method for treating potassium depletion according to claim 1 wherein the potassium chloride is administered as replacement for potassium depletion arising from diuretic therapy.
Claim 7
Dependent Claim 90 words
A combination diet and therapeutic program for maintaining the potassium requirement of a mammal having a need for potassium, which program comprises feeding the mammal foods high in potassium, and administering to the mammal a composition comprising from 15 milligrams to 1200 milligrams of potassium chloride, and a member from the group consisting of salicylic acid and the pharmaceutically acceptable salts of salicylic acid in an effective amount for lessening the incidence of side effects associated with the use of potassium chloride, thereby maintaining the potassium requirements of the mammal.
Claim 8
Dependent Claim 90 words
A combination diet and therapeutic program for maintaining the potassium requirement of a mammal having a need for potassium, which program comprises feeding the mammal foods high in potassium, and administering to the mammal a composition comprising from 15 milligrams to 1200 milligrams of potassium chloride, and a member from the group consisting of salicylic acid and the pharmaceutically acceptable salts of salicylic acid in an effective amount for lessening the incidence of side effects associated with the use of potassium chloride, thereby maintaining the potassium requirements of the mammal.
Claim 9
Independent Claim 79 words
A method for reversing a potassium deficit in a mammal induced by potassium losses from the gastrointestinal tract and the genitourinary system of the mammal, the improvement comprising administering to the mammal a composition comprising 15 milligrams to 1200 milligrams of potassium chloride and a member selected from the group consisting of salicylic acid and its pharmaceutically acceptable salts in an effective amount for lessening the incidence of unwanted side effects associated with the use of potassium chloride therapy.
Claim 10
Independent Claim 79 words
A method for reversing a potassium deficit in a mammal induced by potassium losses from the gastrointestinal tract and the genitourinary system of the mammal, the improvement comprising administering to the mammal a composition comprising 15 milligrams to 1200 milligrams of potassium chloride and a member selected from the group consisting of salicylic acid and its pharmaceutically acceptable salts in an effective amount for lessening the incidence of unwanted side effects associated with the use of potassium chloride therapy.
Claim 11
Independent Claim 66 words
A method for managing the potassium requirement of an animal in need of exogenous potassium, which method comprises administering orally to the animal a dosage formulation comprising 15 milligrams to 1200 milligrams of potassium chloride and an effective amount of a member selected from the group consisting of salicylic acid and its pharmaceutically acceptable salicylate salts for reducing unwanted side effects arising from potassium chloride therapy.
Claim 12
Independent Claim 66 words
A method for managing the potassium requirement of an animal in need of exogenous potassium, which method comprises administering orally to the animal a dosage formulation comprising 15 milligrams to 1200 milligrams of potassium chloride and an effective amount of a member selected from the group consisting of salicylic acid and its pharmaceutically acceptable salicylate salts for reducing unwanted side effects arising from potassium chloride therapy.
Claim 13
Dependent Claim 58 words
A pharmaceutical composition comprising a therapeutically effective amount of potassium chloride for potassium therapy, and about 0.5 milligrams to 5 milligrams of a member selected from the group consisting of salicylic acid and its pharmaceutically acceptable salicylate salts for each 5 milligrams to 20 milligrams of potassium chloride for lessening the unwanted effect arising from the potassium therapy.
Claim 14
Dependent Claim 58 words
A pharmaceutical composition comprising a therapeutically effective amount of potassium chloride for potassium therapy, and about 0.5 milligrams to 5 milligrams of a member selected from the group consisting of salicylic acid and its pharmaceutically acceptable salicylate salts for each 5 milligrams to 20 milligrams of potassium chloride for lessening the unwanted effect arising from the potassium therapy.
Claim 15
Dependent Claim 17 words
The pharmaceutical compositions according to claim 9 wherein the composition is dispersed in a pharmaceutically acceptable polymer.
Claim 16
Dependent Claim 16 words
The pharmaceutical composition according to claim 9 wherein the composition is dispersed in a wax matrix.
Claim 17
Dependent Claim 16 words
The pharmaceutical composition according to claim 9 wherein the composition is in a drug delivery device.
Claim 18
Dependent Claim 13 words
The pharmaceutical composition according to claim 9 wherein the composition is a tablet.
Claim 19
Dependent Claim 53 words
A pharmaceutical composition for potassium replacement therapy, wherein the composition comprises from 15 milligrams to 1200 milligrams of potassium chloride, and an effective amount of a member selected from the group consisting essentially of salicylic acid and its pharmaceutically acceptable salicylate salts for lessening the unwanted side effects from said potassium replacement therapy.
Claim 20
Dependent Claim 53 words
A pharmaceutical composition for potassium replacement therapy, wherein the composition comprises from 15 milligrams to 1200 milligrams of potassium chloride, and an effective amount of a member selected from the group consisting essentially of salicylic acid and its pharmaceutically acceptable salicylate salts for lessening the unwanted side effects from said potassium replacement therapy.
Claim 21
Dependent Claim 29 words
The pharmaceutical composition according to claim 9 wherein the composition comprises 0.5 milligrams to 5 milligrams of the salicylic salt, sodium salicylate, for each 15 milligrams of potassium chloride.
Claim 22
Dependent Claim 34 words
The pharmaceutical composition according to claim 14 wherein the composition comprises 1 milligram to 8 milligrams of the member selected from the group consisting essentially of salicylic acid and its pharmaceutically acceptable salicylate salts.
Claim 23
Dependent Claim 29 words
The pharmaceutical composition according to claim 9 wherein the composition comprises 0.5 milligrams to 5 milligrams of the salicylate salt, potassium salicylate, for each 15 milligrams of potassium chloride.
Claim 24
Dependent Claim 26 words
The pharmaceutical composition according to claim 9 wherein the composition comprises 0.5 milligrams to 5 milligrams of salicylic acid for each 15 milligrams of potassium chloride.
Claim 25
Dependent Claim 25 words
A method according to claim 1 wherein about 0.5 milligram to 5 milligrams of said salicylic acid or salicylate member is administered to the animal.

References Cited (Backward Citations)

US3337404A Cited
US3822344A Cited
US3676553A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1985-10-04 1986-04-05 1986-10-05 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1989-10-04 1990-04-05 1990-10-05 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1993-10-04 1994-04-05 1994-10-05 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag